Drug withdrawals from the Canadian market for safety reasons, 1963-2004

CMAJ. Canadian Medical Association Journal

Volumn 172, Issue 6, 2005, Pages 765-767

  Lexchin, Joel ^a,b,c,d  

^a YORK UNIVERSITY   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BENOXAPROFEN; CERIVASTATIN; CISAPRIDE; DEXFENFLURAMINE; ENZYME INHIBITOR; ETRETINATE; FENFLURAMINE; GEMFIBROZIL; NEFAZODONE; NEOMYCIN; NIALAMIDE; NON PRESCRIPTION DRUG; PEMOLINE; PHENYLPROPANOLAMINE; TROGLITAZONE; URETHAN;

AGRANULOCYTOSIS; BLOOD DYSCRASIA; CANADA; DRUG APPROVAL; DRUG INDUSTRY; DRUG MARKETING; DRUG SAFETY; DRUG SCREENING; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; FOOD AND DRUG ADMINISTRATION; HEART ARRHYTHMIA; HEMOLYTIC ANEMIA; HUMAN; LIVER TOXICITY; NOTE; PRESCRIPTION; RHABDOMYOLYSIS; VALVULAR HEART DISEASE;

EID: 15244362887     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.045021     Document Type: Note

References (27)

1. KPMG Consulting LP. Review of the Therapeutic Products Programme cost recovery initiative. Ottawa: Ministry of Health; 2000.
2. Canada's Research-Based Pharmaceutical Companies. Improving health through innovation: a new deal for Canadians [press release]. Ottawa; September 2002.
3. Office of Inspector General. FDA's review process for new drug applications: a management review. Washington: Department of Health and Human Services; March 2003.
4. Abraham J, Davis C. Mapping the social and political dynamics of drug safety withdrawals in the UK and the US. Sussex: Economic and Social Research Council; 2002.
5. Lurie P, Wolfe SM. FDA medical officers report lower standards permit dangerous drug approvals. Washington: Public Citizen; 1998.
6. Pugsley LI. The administration and development of federal statutes on foods and drugs in Canada. Med Serv J Can 1967;23:387-449.
7. Rawson NSB, Kaitin KI. Canadian and US drug approval times and safely considerations. Ann Pharmacother 2003;37:1403-8.
8. Bakke OM, Wardell WM, Lasagna L. Drug discontinuations in the United Kingdom and the United States, 1964 to 1983: issues of safety. Clin Pharmacol Ther 1984;35:559-67.
9. Bakke OM, Manocchia M, de Abajo F, Kaitin KI, Lasagna L. Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: a regulatory perspective. Clin Pharmacol Ther 1995;58:108-17.
10. Friedman MA, Woodcock J, Lumpkin MM, Shuren JE, Hass AE, Thompson LJ. The safety of newly approved medicines: do recent market removals mean there is a problem? JAMA 1999;281:1728-34.
11. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. JAMA 2002;287:2215-20.
12. Department of Economic and Social Affairs. Consolidated list of products whose consumption and/or sale have been banned, withdrawn, severely restricted or not approved by government. Eighth issue: Pharmaceuticals. New York: United Nations; 2003.
13. Hughes FN, editor. Compendium of Pharmaceutical Specialties, 1st ed. Toronto: Canadian Pharmaceutical Association; 1960.
14. Repchinsky C, editor. Compendium of Pharmaceuticals and Specialties, 37th ed. Ottawa: Canadian Pharmacists Association; 2004.
15. The top 200 drugs of 2001. Pharm Pract 2001;17(12):3,4,6,8,13,22.
16. The top 200 drugs of 1997. Pharm Pract 1997;13(12):29,30,2,4,6,9,40.
17. Decima Research Inc. Public opinion survey on key issues pertaining to post-market surveillance of marketed health products in Canada. Health Canada; 2003. Report No.: POR# 298-02.
18. Therapeutic Products Directorate. Cerivastatin (Baycol®) and gemfibrozil - increased risk of rhabdomyolysis - concomitant use contraindicated. Ottawa: The Directorate; 2001 July 16.
19. Targeting doctors. Toronto: Canadian Broadcasting Corporation; 2002. Available: www.cbc.ca/disclosure/archives/0103_pharm/resources.html (ac-cessed 2005 Jan 27).
20. Cisapride: arrhythmia awareness. Canadian Adverse Drug Reaction Newsletter 1996;6(3):1, 2.
21. Cisapride (Prepulsid®): interactions with grapefruit and drugs. Can Adverse Drug React Newsl 2000;10(1):1-3.
22. The top 200 drugs of 1999. Pharm Pract 1999;15(12):4,6,7,39-42.
23. Lexchin J. New drugs with novel therapeutic characteristics: have they been subject to randomized controlled trials? Can Fam Physician 2002;48:1487-92.
24. Lexchin J. New directions in drug approval. CMAJ 2004;171:229-30.
25. Adverse drug reaction reporting - 1998. Can Adverse Drug React Newsl 1999;9(2):5.
26. Adverse reaction reporting - 2003. Can Adverse React Newsl 2004;14(2):2.
27. Improving Canada's regulatory process for therapeutic products: building the action plan. Public Policy Forum multi-stakeholder consultation, 2003 [presentation]. Available: www.ppforum.ca/ow/ow_e_05_2003/ Presentation%20 _Overview_of_Action_Plan.pdf (accessed 2005 Jan 27).